A dirty secret of the antibody world is that most antibodies don't work. A large study generated comparative data proving DNA-encoded antigens produce quality antibodies at a much higher success rate than with peptide antigens.
Published originally in 2011, the 2012 version of the ePoster features a new organ -- the pancreas -- plus updates for the existing organs to reflect key advances of the past year.
Economists propose a US$30 billion boost to biomedical R&D doi:10.1038/nrd3857 Economists hope they can attract billions of dollars for drug R&D by securitizing research projects. Could they close the innovation gap in the process? Full Text
Moving from an asthma pipe dream to a pipeline doi:10.1038/nrd3858 After decades of stubbornly slow progress in asthma drug development, recent results from a trial of GlaxoSmithKline's mepolizumab hint at a brighter future. Full Text
Biobusiness Briefs: Dual-acting combination meets heart failure end point doi:10.1038/nrd3855 Novartis has announced positive results from the Phase II trial of its first-in-class angiotensin receptor neprilysin inhibitor combination, LCZ696. Full Text
Market watch: Upcoming market catalysts in Q4 2012 doi:10.1038/nrd3856 Key market catalysts include an expected decision by the FDA on the approval of the anticancer drug cabozantinib; results from a trial of the peptide NX-1207 in benign prostatic hypertrophy; and results from a trial of interferon-free regimens for HCV infection. Full Text
Resetting the clock in diabetes doi:10.1038/scibx.2012.995 Researchers have evidence that pancreatic islet β cells do not die but rather dedifferentiate in mouse models of type 1 and type 2 diabetes. The findings suggest that reawakening these dormant cells might restore insulin secretion in diabetics. Full Text
From the analyst's couch: Autism spectrum disorders doi:10.1038/nrd3771 This analysis looks at the increasing number of candidates in the pipeline for autism spectrum disorders, reflecting the increasing prevalence of autism and the growing interest in finding novel treatments. Full Text
Neurodegenerative diseases: Anti-epileptic drug shows benefit in AD mouse model doi:10.1038/nrd3850 Using a mouse model engineered to overexpress human amyloid precursor protein and amyloid-β, researchers have shown that cognitive and synaptic deficits are caused by aberrant neuronal network activity, and that this can be improved with an anti-epileptic drug. Full Text
Vaccines: Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine? doi:10.1038/nrd3854 A new vaccine platform based on self-amplifying RNA encapsulated in synthetic lipid nanoparticles overcomes some of the limitations of earlier nucleic-acid-based approaches. Full Text
Metabolic disorders: Safe cannabinoid receptor modulators in sight? doi:10.1038/nrd3851 A peripherally selective CB1R inverse agonist can safely and effectively reduce body weight in a mouse model of obesity, without affecting behaviour. Full Text
Targeting the TGFβ signalling pathway in disease doi:10.1038/nrd3810 This Review considers why the TGFβ signalling pathway is a drug target, the potential clinical applications of TGFβ inhibition, the issues arising with anti-TGFβ therapy and how these might be tackled. Full Text
Targeting cells in chronic inflammation doi:10.1038/nrd3794 This Review focuses on the current knowledge of the IL-17–TH17 cell pathway to better understand the positive as well as potential negative consequences of targeting them. Full Text
Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract doi:10.1038/nm.2932 Researchers describe a molecular cascade whereby mutant androgen receptor upregulates CGRP in neuronal cells, promoting JNK activation and degeneration. The 5-HT1B/1D receptor agonist naratriptan decreases CGRP expression and improves motor performance in a mouse model of SBMA. Full Text
Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function doi:10.1038/nchembio.1081 Researchers propose that compounds binding a newly discovered allosteric site of the hepatitis C virus’s NS3 protein may inhibit its function, and thus represent a new class of direct-acting antiviral agents. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment